Challenges of Animal Health Product Packaging: Two Perspectives
Diane Sudduth, M.S., D.V.M., Director, Regulatory Affairs, Animal Health Institute, Washington, D.C.

False Claims of FDA Approval Are Actionable Under the Lanham Act
by Douglas J. Behr, Partner in the litigation group at Keller and Heckman LLP , Washington, D.C .

Livestock Patents: Possible USPTO Consideration of Patent Applications Covering a Breed of Farm Animal
by John B. Reiss, Ph.D., Chair of the Health Law Practice Group, and a member of the Life Sciences Practice Group in the Philadelphia, PA office of Saul Ewing, LLP
and
Aida Lebbos, member of the Technology Transactions and Intellectual Property and Life Sciences practices in the Baltimore, MD office of Saul Ewing, LLP.

Approaching 30 Years—The Cosmetic Ingredient Review Program
by F. Alan Andersen, Ph.D., Director and Scientific Coordinator of the Cosmetic Ingredient Review in Washington, D.C. since 1993. Prior to then, he spent 22 years at the Food and Drug Administration in radiological health and medical devices.

Benefits from the Scientific Side of Cosmetics
by Phillip L. Casterton, M.S., D.A.B.T., Toxicologist with the Burdock Group, Vero Beach, FL.

Are U.S. Cosmetic Regulatory Policies Keeping Consumers Safe?
by Esam Z. Dajani, Ph.D., FACG, Founder of IDDC Corporation, a contract pharmaceutical research organization, Long Grove, IL and Adjunct Professor of Medicine at Stritch School of Medicine, Loyola University Medical Center, Maywood, IL
and
Mona E. Dajani, M.B.A., J.D., Attorney at Sonnenschein Nath & Rosenthal, LLP, Chicago, IL.

Cosmetic Tax
by Robert T. Bohannon, Manager, State Government Affairs, American Academy of Dermatology Association, Washington, D.C.

New Rules for Labeling and Importation of Cosmetics in Canada
by Cynthia Tape, who practices intellectual property law in the Toronto office of Torys LLP
and
Ingrid VanderElst, who practices intellectual property law in the Toronto office of Torys LLP.

Qualified Health Claims: Creatures of Case Law
by Diane B. McColl, Principal with the law firm of Hyman, Phelps & McNamara, P.C., Washington, D.C.
and
Christine P. Bump, Associate with the law firm of Hyman, Phelps & McNamara, P.C., Washington, D.C.

The Brave New(?) World of Personalized Medicine
by Henry I. Miller, M.D., Fellow at the Hoover Institution (Stanford University, Stanford, CA) and the Competitive Enterprise Institute (Washington, D.C.). Dr. Miller was a Food and Drug Administration official from 1979 to 1994.

Exaggerated Response or Necessary Change?
by Marsha N. Cohen, Professor of Law, Hastings College of the Law (University of California), San Francisco, CA.

History Corner
In Roosevelt's Name We Bust Trusts: The Meat Inspection Act of 1906
by Suzanne White Junod, Ph.D., Historian with the Food and Drug Administration, Rockville, MD.

Enforcement Corner
Application of the Attorney-Client Privilege to Former Employees: Less Than You Might Think
by Steven M. Kowal, Chair of the White Collar Criminal Defense Group at the law firm of Bell, Boyd & Lloyd, LLC , Chicago, IL.

Global Corner
From Basic Chemicals to Consumer Products: The Implications of Nanotechnology by Matthew R. Weinberg, Chief Executive Officer, THE WEINBERG GROUP, Washington, D.C.

Associates' Corner
Medicare Part D—An End to the Rx Drug Reimportation Controversy?
by Rene Y. Quashie, Senior Associate with Fulbright & Jaworski L.L.P., Washington, D.C.

Note: All author affiliations are current as of the date of publication of the issue.